2. Signaling Pathways
  3. Metabolic Enzyme/Protease
  4. N-myristoyltransferase
  5. N-myristoyltransferase Inhibitor

N-myristoyltransferase Inhibitor

N-myristoyltransferase Inhibitors (4):

Cat. No. Product Name Effect Purity
  • HY-147308
    Zelenirstat
    		Inhibitor 99.05%
    Zelenirstat is an orally acitve, small-molecule, dual N-myristoyltransferase (NMT) inhibitor, with IC50s of 5 nM (NMT1) and 8 nM (NMT2), respectively. Zelenirstat can induce cell apoptosis, has anti-cancer activity, inhibits early B cell receptor (BCR) signaling, and can be used to study malignant lymphoma.
  • HY-164285
    MYX1715
    		Inhibitor 98.31%
    MYX1715 is an inhibitor of N-Myristoyltransferase (NMT) with a KD value of 0.09 nM. MYX1715 inhibits the proliferation of LU0884 and LU2511 with IC50 values of 44 nM and 9 nM. MYX1715 exhibits antitumor efficacy against neuroblastoma and gastric cancer in mouse models. MYX1715 can be used as ADC toxin.
  • HY-136625
    LY134046
    		Inhibitor
    LY134046 is an inhibitor of norepinephrine N-methyltransferase (NMT) with cardiovascular activity. LY134046 causes sustained reductions in mean arterial blood pressure and heart rate, but no significant reductions in norepinephrine concentrations in the rat brain. LY134046 does not interact with adrenergic or cholinergic receptors, and its hypotensive and bradycardic effects do not require neurogenic tension. LY134046 (40 mg/kg/day) causes sustained and significant inhibition of hypothalamic and brainstem NMT activity, resulting in central norepinephrine depletion.
  • HY-160945
    NMT-IN-7
    		Inhibitor
    NMT-IN-7 is a N-myristoyl transferase (NMT) inhibitor, with IC50s of 2.1 nM for HsNMT1M, 0.6 nM for SU-DHL-10 cell. NMT-IN-7 can be used as a ADC cytotoxin.